Neurology

PET with 6-fluoro-(¹⁸F)-L-dopa is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum. It can be used for diagnosis of Parkinson’s disease and differentiation between essential tremor and parkinsonian syndromes.

Oncology

Among medical imaging modalities, PET with 6-fluoro-(¹⁸F)-L-dopa provides a functional approach of pathologies, organs or tissues where enhanced intracellular transport and decarboxylation of the amino acid dihydroxyphenylalanine is the diagnostic target. The following indications have been particularly documented:

Diagnosis

• Diagnosis and localisation of focal hyperplasia of beta islet cells in the case of hyperinsulinism in infants and children
• Diagnosis and localisation of paragangliomas in patients with a gene mutation of the succinate dehydrogenase D variant
• Localisation of pheochromocytoma

Staging

• Phaeochromocytoma and paraganglioma
• Well differentiated neuroendocrine tumours of midgut.

Detection in case of reasonable suspicion of recurrences or residual disease

• Primary brain tumours of all grades of differentiation.
• Phaeochromocytoma and paraganglioma
• Medullary thyroid cancer with elevated serum levels of calcitonin
• Well differentiated neuroendocrine tumours of midgut
• Other endocrine digestive tumours when somatostatin receptor scintigraphy is negativeThis medicinal product is for diagnostic use only.